IRIDEX Corporation (IRIX) Earnings Call Transcript & Summary
May 19, 2026
What were the key takeaways from IRIDEX Corporation's May 19, 2026 earnings call?
In the first quarter of 2026, IRIDEX Corporation reported revenues of $11.8 million, essentially flat year-over-year, and a net loss of $0.5 million, an improvement from a loss of $1.7 million in the same period last year. Management reaffirmed full-year revenue guidance of $51 million to $53 million, indicating a pro forma growth of 1% to 5% compared to 2025. Key drivers included strong performance in the glaucoma segment, although international headwinds impacted retina sales, particularly in Asia and the Middle East.
What topics did IRIDEX Corporation cover?
- Revenue Performance: IRIDEX reported Q1 2026 revenue of $11.8 million, which was 'essentially flat year-over-year' and above prior guidance. The revenue decline was primarily due to lower retina system sales, partially offset by increased glaucoma probe sales.
- Glaucoma Business Growth: The G6 probes segment showed strong growth with sales increasing to $3.6 million, a 14% year-over-year rise. Management noted that 'the loyalty physicians have to the G6 platform' is driving this growth, despite challenges in other areas.
- International Challenges: Management highlighted 'supply disruptions, regulatory delays, and geopolitical volatility' as significant challenges affecting international revenue, particularly in Asia and the Middle East. This environment has created headwinds for overall sales.
- Cost Management Initiatives: Operating expenses decreased by 4% year-over-year to $5.1 million, attributed to lower general and administrative costs. The relocation of certain functions out of California is expected to yield annual savings of approximately $600,000.
- Regulatory and Supply Chain Improvements: Management indicated that 'supply chain conditions and regulatory processes are improving,' suggesting potential for revenue recovery in the upcoming quarters. They expect 'incremental revenue opportunities for the balance of the year.'
What were IRIDEX Corporation's May 19, 2026 results?
- Revenue: $11.8 million (vs $11.9 million in Q1 2025, inline with expectations)
- Net Loss: $0.5 million (vs $1.7 million in Q1 2025, improved performance)
- Gross Margin: 40% (vs 43% in Q1 2025, decreased due to increased manufacturing costs)
- Operating Expenses: $5.1 million (decreased 4% YoY from $5.3 million)
- Adjusted EBITDA: $0.3 million (vs $0.4 million in Q1 2025, slight decrease)
- Cash and Cash Equivalents: $4.6 million (decreased by $1.4 million in the quarter)
IRIDEX's Q1 results reflect a mixed performance with strong growth in the glaucoma segment but challenges in the retina business due to international issues. The reaffirmed guidance and backlog present potential catalysts for future revenue growth. Investors should monitor the execution of cost management initiatives and the resolution of regulatory challenges as key factors influencing the investment thesis.
Earnings Call Speaker Segments
Thanks. I appreciate everyone joining us on today's call. With me from the company are Patrick Mercer, IRIDEX's Chief Executive Officer, and Romeo Dizon, our Chief Financial Officer. Iridex issued its financial results earlier today for the quarter that closed on 04/04/2026. You can find a copy of the press release on the company's website. Before we get started, I want to remind you that during this call, management will make statements that include forward looking statements within the meaning of federal securities laws are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2 thousand. During this call, we may say things that aren't historical facts — for example, comments about our strategic goals and priorities, our products and development matters, sales trends, and the markets where we operate. Every forward-looking statement reflects what we currently estimate and various assumptions we've made. Such statements carry material risks and uncertainties, and actual results or events could end up differing materially from what those forward-looking statements anticipate or imply. So you shouldn't rely on them; if you want to understand the risks and uncertainties tied to our business, please look at our latest Form 10-K and Form 10-Q filings with the SEC. IRIDEX says it has no plan or duty to refresh or amend any financial projections or forward-looking remarks—unless the law demands it—whether that's prompted by fresh information, later developments, or anything else. What you're hearing on this call is time-sensitive and holds true only as of the live broadcast. That's today, 05/19/2026. With that said, I'll hand things over to Patrick.
Hello, everybody, and thanks for being here this afternoon. It's a pleasure to walk you through what we accomplished in the first quarter, along with the steady headway we're making as we continue building on the favorable trajectory from the prior year. Before we get into Q1 specifics, I'd like to call attention to several notable milestones from last year. During 2025, the company generated positive adjusted EBITDA for the first time in its recent history, and we additionally reached positive cash flow from operations during Q4. Those results mark a fundamental transformation in IRIDEX's financial profile and demonstrate the effort put in to reposition the business so it can deliver sustainable profitability moving forward. Thanks to these efforts and a strong beginning to the year, we still expect to reach positive cash flow in 2026. During Q1, we carried out our plans even with a number of headwinds we had foreseen. These included temporary supply chain issues from the Iran conflict and longer timelines tied to some regulatory approval. Given that situation, our revenue came in at 11.8 million, basically unchanged from a year earlier and higher than the guidance we shared on our previous earnings call. G-Probes, the business with our best margins, stood out as a clear highlight this quarter. Rising growth and uptake of our glaucoma solution highlight how strong our clinical value proposition is and how committed physicians are to the G6 Platform. On the international side, the environment we're dealing with is a tough one — supply disruptions, regulatory delays, and geopolitical volatility are all factors, and they're hitting revenue especially hard in Asia and the Middle East. The key point is that underlying demand is still solid. We also think revenue and earnings would have come in higher if we'd been able to fill certain orders that were sitting in backlog when the quarter ended. Going forward, supply chain conditions and regulatory processes are getting better, and we're continuing to actively manage through these dynamics. So as a result, we believe some of the timing-related impacts that weighed on our first quarter performance represent incremental revenue opportunities for the rest of the year. Turning to how we're running the business, our operating expense came down once more versus the same period a year ago, reflecting our ongoing push for greater efficiency throughout the company. We're happy to share that moving some general and administrative roles out of California is once again producing savings each quarter, beginning in Q1 26, and the shift of our headquarters remains on track for later this year. That move should trim roughly 600 thousand from our fixed cost base on an annualized basis. On top of that, our multiyear effort to move production to lower cost third party contract manufacturers is now underway, with meaningful transfers initiated in the first quarter. We anticipate wrapping up the full rollout during 2027, and as the year moves forward this shift should lift gross margin. That momentum carries into the following year. Now let's look at how we performed commercially during Q1. Beginning with glaucoma. All told, during the first quarter we moved 15.5 thousand G-Probes, compared with 13.9 thousand a year earlier. That figure captured growth inside the crowded glaucoma space, showing just how strong our value proposition is and how dedicated physicians stay to the G6 platform. Reaching G6 adopters whose usage lands at the average level through MedScout continues to be our most effective tactic. Time and again, our MedScout platform demonstrates its value for precisely targeted outreach. We focus our efforts on 2 groups. The first category is made up of sites that have G6 systems in place and are using them at a moderate level. The second category, meanwhile, includes high volume locations that have not yet started doing MicroPulse procedures. When it comes to the mid utilization accounts, our focus is on education — working alongside physicians to expand the criteria they use for selecting patients, so that treatment happens earlier across the glaucoma severity continuum. As for the second group, education remains the top priority as well, particularly by drawing attention to the efficacy observed among TLC patients who have already had a mixed procedure. On the subject of mixed, the Medicare LCD that came out last year is creating favorable momentum for us, including by broadening the segments we target and promoting earlier uptake of G6 therapy for patients with mild to moderate glaucoma as well as those who are post-MIGS. Combined with the improved sweep speed we've introduced, our procedural methods, and the clinical evidence demonstrating how well the procedure lowers IOP, we believe our position is strong for delivering sustainable growth in this business across 2026. Our Q1 results were also bolstered by pricing discipline. With our ASP increasing for both probes and systems in the U.S., an effect carried over from 2025, this points to broader acknowledgment of the value our procedure offers and rising awareness among ophthalmologists that G6 is a safe, effective substitute for incisional surgery. On the systems side, we recorded 24 G6 units during the quarter, matching the equivalent period a year earlier. The number of units placed hasn't changed compared with a year ago, and doctors moving their practices keeps fueling purchases of dedicated systems at newly opened locations. With that installed base expanding at a reliable pace, we have a strong base to build on as we push more probe usage through our commercial plan. Now for our international glaucoma business, results differed by region. We worked through quite a few operational and macroeconomic hurdles. Across Europe, the Middle East, and Africa, we held several high impact G6 symposiums along with clinical trainings, which drove home our value proposition in a number of countries, among them Russia's Saudi Arabia, Egypt, and Poland. The UK registry product is progressing on schedule. We've seen solid involvement from clinicians, and we think that gives us a good foundation to keep growing uptake in the area. When it comes to Germany, G6 probe revenue held steady among the customers we already had, and we feel the utilization level in that market is in a strong spot to take on added volume while we complete distributor changes there. Turning to Asia, we dealt with persistent ups and downs all year long. Interest in what we sell stayed consistent, yet difficult economic circumstances generated certain obstacles for our commercial efforts; in Japan, we brought G-Probe inventory back to normal after earlier regulatory hurdles. That was a significant favorable step forward for the region. But challenges stemming from a weekend's broader economic pressures are still with us; we're keeping a close watch on that landscape and anticipate that things will get better eventually. When it comes to Latin America and Canada, G-Probe results held steady, with Peru and Mexico driving the user numbers. We're putting extra emphasis on Canada, Brazil, and Argentina so we can capitalize on the large G6 system installed base. Now shifting to our retina offerings. Our strategic focus stays on 3 key areas. Pushing the U. S. PASCAL upgrade cycle, growing PASCAL adoption abroad, and securing regulatory approvals for our next generation platforms so we can take advantage of our established global distribution footprint; within The United States, surgical retina stood out, powered by ongoing robust demand for SLx Tx and LIOs. This category beat expectations for the quarter and showed just how strong our surgical platforms are underneath. Medical retina kept delivering strong results, especially PASCAL, thanks to a solid pipeline of leads that came out of the American Academy of Ophthalmology annual mean Q4. It's worth pointing out that PASCAL remains firmly our flagship system in The U. S. Market; we're observing a steady pattern of current PASCAL customers moving up to our newer platforms. And doctors just finishing their ophthalmology training are choosing PASCAL systems because of what we've done to make PASCAL the go-to system in university and training programs.
Regarding our commercial activities, during the first part of April we made public a key alliance with iPro GPO. Thanks to this deal, a greater number of customers can obtain our retina laser offerings — specifically, over 1.8 thousand members, a group that encompasses ophthalmology practices, ambulatory surgery centers, and hospitals located in The United States. Under the terms of this arrangement, those who belong to iPro GPO are offered preferential rates for our PASCAL laser platform, the IQ 532 and IQ 577 models, along with the Oculight SLx laser. This builds upon the Cyclo G6 agreement we already have in place with Ipro GPO and marks a notable achievement on the commercial side. Moving past the contractual aspect, it strengthens the trustworthiness of our check technology, allows a smoother selling cycle for both our staff and buyers, and widens the potential customer base for our retinal laser offering. We anticipate that this alliance will serve as a key catalyst for retina system installations over the next several quarters. Shifting to retina efforts abroad, in Europe, the Middle East, and Africa: a shortage of MDR clearance keeps holding back PASCAL expansion throughout Europe, though this is somewhat balanced out by the introduction of the new IRIDEX PASCAL in Africa. Within Germany, EndoProbe cells are building momentum, consistent with our strategy, as we assume the business previously handled by our distributor. Regarding Asia, China faced certain difficulties in the quarter, among them EndoProbe supply limitations that significantly hurt sell-through. We have been collaborating with our production partners, and these matters ought to be settled within this month; in Japan, sizable Pascal orders got pushed into Q2 because of regulatory holdups tied to electrical safety testing; this stems from timing rather than any drop in demand, and we anticipate the order will go out during the present quarter. In Latin America and Canada, PASCAL and medical retina cells fell short of what we expected, affected partly by the usual slowdown from summer holidays. Looking toward the rest of 2026, our strategic objectives stay well-defined and concentrated; for the entire year of 2026, we are restating our revenue outlook of $51 million to $53 million. As a point of reference, this outlook leaves out revenue from the Middle East region and equates to roughly 1% to 5% pro forma growth compared with 2025. I take pride in the steady execution we have shown across all 4 of our 2025 commitments: revenue growth, cost reduction, positive adjusted EBITDA, and positive cash flow from operations in Q4. The groundwork is laid for ongoing advancement in 2026. At this point I will pass the call to Romeo so he can go over our financial results. Thank you, Patrick.
Good afternoon, everyone, and thank you for joining us today. As noted in our press release and in Patrick's comments, total revenues for 2026 reached 11.8 million, basically flat against the 11.9 million reported for 2025. That top-line number was in line with what we expected and with the guidance issued alongside our Q4 results. The drop in revenue primarily reflected weaker retina system sales, partially offset by stronger glaucoma probe sales as well as service and other revenues. Retina product revenue was $5.8 million, compared with $6.6 million in the same period last year, mostly due to softer international sell through of retina systems. Cyclo G6 line sales totaled $3.6 million, up 14% year over year from $3.2 million in the comparable quarter a year ago. That gain reflected moving more units both domestically and internationally, plus stronger domestic ASB. Revenue beyond that category rose $200 thousand to $2.3 million in 2026 from $2.1 million in 2025, driven largely by service and select other legacy products. For 2026, profit was $4.7 million, representing a 40% gross margin, down $300 thousand from $5 million in the prior year period, which was a 43% gross margin. The primary factor behind the lower gross margin was an increase in overall manufacturing cost, including elevated product costs tied to the recent tariff development. Sequentially, first quarter gross margins were 300 basis points above where they stood in the fourth quarter 25. Operating expenses totaled $5.1 million in the 2026, a reduction of $200 thousand, or 4%, from $5.3 million in 2025. That decline stemmed mostly from lower general and administrative expenses, reflecting decreased consulting costs, decreased deal related legal expenses, and savings from the general and administrative transfer initiative discussed in the prior period. During Q4, we announced plans to relocate certain G&A functions out of California beginning in the 2026. On that initiative, we're about 70% of the way through, and through 2026 we've realized roughly $100 thousand in savings, Scott — falling short of the roughly $165 thousand quarterly benefit we had anticipated. We'll share progress with you on our next call. Our operating loss was $300 thousand, which is $100 thousand wider than the $200 thousand operating loss posted in 2025. For 2026, other expense, net, came to $100 thousand, consisting mainly of interest plus amortization related to loan expenses. In 2025, other expense, net, was $1.5 million, driven largely by costs associated with settling a note payable. Consequently, we posted a net loss of $500 thousand, or $0.03 per share, for 2026, against a net loss of $1.7 million, or $0.10 per share, in the equivalent period a year earlier. For the quarter, non-GAAP adjusted EBITDA was $300 thousand, versus $400 thousand in 2025. That fell roughly $165,000 short of the benefit we had anticipated for the quarter. As of 04/04/2026, cash and cash equivalents totaled $4.6 million, a drop of $1.4 million across the quarter. On our last call, we noted that cash consumption typically peaks during the first quarter of the fiscal year, since that is when we pay out accrued compensation along with other liabilities and accrued expenses carried over from year end. Through the remainder of the year, we expect to generate cash, and we anticipate quarterly cash generation improving progressively as inventory is sold and receivables are gathered on higher revenues. All together, that amounts to positive cash flow for fiscal year 2026. Total operating expenses followed a favorable trend in Q1 26, reflecting the sustained impact of the cost reduction actions we began in 2024. Our first quarter performance demonstrates that 2026 remains on track. The sequential revenue decline in Q1 was expected, as it aligns with our business's normal seasonality, and despite that lower revenue we still reduced our net loss. As Patrick mentioned, we are reaffirming 2026 guidance. Revenue should fall between $51 million and $53 million. Due to market disruption related to the ongoing conflict in The Middle East, this guidance excludes revenue from that region. On a pro forma basis, adjusted to remove Middle East revenue in 2025, the guidance suggests 2026 growth of 1% to 5% compared with 2025. We'd also like to restate the seasonality our business experiences. Q1 usually represents about 22% of annual revenue and is the smallest quarterly revenue figure of the year. Looking at the full picture in dollar terms, Q2 and Q4 are generally busier than Q1, with Q4 being the year's peak period, while Q3 typically marks a step down from Q2. Similarly, we're restating our tax guidance for adjusted operating expenses — which exclude depreciation, amortization, and stock comp — placing them at $19 million to $19.5 million for all of 2026. Additionally, we continue to expect positive operating cash flow throughout all of 2026. With that said, I'll hand things back to Patrick.
Thanks, Romeo. Looking back at Q1, the strides we're making with our strategic initiatives give me reason for optimism. Within a fiercely competitive landscape, our U.S. Glaucoma business turned in strong growth. The gains from our cost structure work are coming through as expected, and the shift in manufacturing is in motion, staying on schedule to produce substantial margin growth. Our confidence remains firm that we can meet our 2026 priorities. Those priorities are straightforward: grow G6 utilization by targeting effectively, secure further regulatory clearances abroad to open up additional geographies for our retina systems, and keep moving toward cheaper contract manufacturers to enhance gross margin; at this point, I'll hand things over to the operator so we can take your questions.
Thanks, and good afternoon. That was a lot to take in. To begin with, regarding the Retina line, one of the softer quarters we've had recently — is that mostly tied to the international headwinds? Is there anything else going on? And looking ahead to full year 2026, I recall last year being a strong one for retina. Should we expect that comparison to push 2026 into a decline versus the prior year for retina revenues?
Hi, Scott. Thanks for asking. So in the first quarter, we hit some regulatory delays that set us back internationally. That was especially true for Pascal — orders didn't ship to Japan because of it. Some other orders also didn't ship because of a material problem with our EndoProbes. We've fixed that problem, and the product ships this month. The regulatory matters are also settled now. So as we move forward, we don't view these as problems at all. Actually, our PASCAL in The US did really well, and so did our surgical retina; so going forward, we don't anticipate anything changing. We still expect the Pascal upgrade cycle to keep going, both international and in The US. We've been working with hospitals and universities so graduating ophthalmologists begin using our PASCAL systems; and especially with this iPro GPO partnership, we expect improvement over Q1. In Q1, a handful of supply chain and regulatory challenges tripped us up, but with luck those are behind us. We're confident that, certainly, as we move ahead, they will be.
All right, that's helpful. So you brought up some backlog when the quarter closed. I missed it — did you put a figure on how much that was? And is that going to help us in Q2? Also, was that backlog sitting in retina, or over in G6?
The backlog came to roughly $800 thousand, and every bit of it was retina. The EndoProbe backlog, we saw that one coming; the regulatory piece, we didn't. We'd been hoping to push it across the finish line. But as you're aware, when it comes to regulatory matters, certain of those decisions rest with the authorities in those countries. Looking ahead, though, we expect that revenue to go out the door during this quarter — and yes.
All right, that's good. And now, if we turn to G6, the number of systems that were sold didn't change compared with the prior year. Do you believe you're able to increase the overall systems sold during 2026? Or will the emphasis instead be placed more heavily on the probes, which performed, as you're aware, quite strongly? During the quarter.
Yes. As we see it, we'll expand the system to some degree, yet our primary attention is on boosting probe utilization and on reaching especially those patients whose condition is more moderate. Within the U.S., 2.1 million patients are moderate, and we have barely begun to address that group; and through our MedScout targeting, we're pursuing the places where we're able to determine, as you know, which procedures are being performed by whom. Our ongoing emphasis will be on utilization and on selling additional probes. Naturally, we're bringing on new accounts, and we expect those figures to stay consistent with what we've anticipated and with our plan. Yet what we truly aim for — what we truly aim for — is to raise probe utilization; and, as you know, one thing to keep in mind is that within the U.S. in particular, we raised ASP for both the probes and the systems; therefore we experienced growth, clearly, from the ASP, and from units too. And that's something we're enthusiastic about. We have a lot of confidence in our glaucoma business as we move through the remainder of the year.
All right. Excellent. One last thing I wanted to ask. Our gross margin rose quarter over quarter during Q1. Yet in the prior year, it dropped during those intervening periods. What's the right way to view gross margin for Q2 and Q3 compared with the figure we just posted? Thanks.
Hello, Scott. Romeo here. Appreciate you asking. Yes. Essentially, as we move forward, over the past 2 quarters we've been examining the reserves tied to the contract manufacturing transition of products. So we calculated those part costs. Our plan was to expense them at that point. That's the reason margins came in lower. Still, despite our production cost continuing to climb, I'd say they've settled into the high 30s, low 40s, though it truly hinges on product and region mix too, and that combination gave us a lift this quarter.
All right, that's excellent. I appreciate the detail, Romeo, and thanks for fielding the questions.
We appreciate you spending part of your day with us, Scott. We're eager to share our progress with you on upcoming calls. Thanks very much.
Everyone, that brings us to the end of this session. Thanks to each of you for being here. You can go ahead and hang up now. Thanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IRIDEX Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IRIDEX Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.